(Q40750547)

23 September 2017

1 reference

title

New progestins--clinical experiences: gestodene (English)

1 reference

23 September 2017

Shoupe D

1

1 reference

PubMed ID

8178907

23 September 2017

language of work or name

English

0 references

publication date

1 May 1994

1 reference

American Journal of Obstetrics and Gynecology

23 September 2017

1 reference

23 September 2017

170

1 reference

23 September 2017

5 Pt 2

1 reference

23 September 2017

1562-1568

1 reference

Clinical experience with a modern low-dose oral contraceptive in almost 100,000 users

23 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Clinical acceptability of monophasic gestodene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Gestoden, an innovative progestogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Oral contraceptive type and functional ovarian cysts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

A study comparing a gestoden triphasic formulation with a fixed combination OC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Comparative trial of the effects on glucose tolerance and lipoprotein metabolism of two new oral contraceptives containing gestoden and desogestrel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Effects of seven low dose combined oral contraceptives on high density lipoprotein subfractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Changes in lipid metabolism during 12 months of treatment with two oral contraceptives containing 30 micrograms ethinylestradiol and 75 micrograms gestodene or 150 micrograms desogestrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Effects of three low-dose oral contraceptive formulations on lipid metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Estrogenic effect of gestodene- or desogestrel-containing oral contraceptives on lipoprotein metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Metabolic effects of three new low-dose pills: a six-month experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Clinical and metabolic effects of a pill containing 30 mcg ethinylestradiol plus 75 mcg gestodene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Comparison of two triphasic contraceptives with different progestogens: effects on metabolism and coagulation proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Metabolic investigations with Femodene--an oral contraceptive containing gestodene and ethinyloestradiol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Comparative studies of 30 micrograms ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Lipid metabolism and coagulation of two contraceptives: correlation to serum concentrations of levonorgestrel and gestodene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Effects of two triphasic oral contraceptives containing ethinylestradiol plus levonorgestrel or gestodene on blood coagulation and fibrinolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Effects of long-term gestodene-containing oral contraceptive administration on hemostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

A comparison of the effects of two triphasic oral contraceptives on haemostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Metabolic changes during treatment with two different progestogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Effect of two oral contraceptives containing 30 micrograms ethinylestradiol and 75 micrograms gestodene or 150 micrograms desogestrel upon various hormonal parameters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

Protein binding of active ingredients and comparison of serum ethinyl estradiol, sex hormone-binding globulin, corticosteroid-binding globulin, and cortisol levels in women using a combination of gestodene/ethinyl estradiol (Femovan) or a combinatio

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2905020-9

10.1016/S0002-9378(94)05020-9

7 January 2021

Identifiers

DOI

1 reference

23 September 2017

1 reference

PubMed ID

8178907